• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with adhd medication making it worse face a difficult decision regarding whether or not to stop taking adhd medication guanfacine medication during pregnancy and breast-feeding. Little data exists about how long-term exposure to these medications could affect the fetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus do not develop neurological conditions like hearing or vision impairment seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality research.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication need to weigh the benefits of taking it against the potential risks for the foetus. Physicians do not have the necessary data to give clear guidelines however they can provide information on risks and benefits that assist pregnant women in making informed decisions.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during their early pregnancy were not at higher risk of fetal malformations or structural birth defects. Researchers conducted a large population-based case-control study to evaluate the incidence of major structural birth defects in babies born to mothers who took stimulants during early pregnancy, and those who did not. Clinical geneticists, pediatric cardiologists and other experts reviewed the cases in order to make sure that the classification was accurate and to eliminate any bias.

However, the study had its limitations. In particular, they were unable to distinguish the effects of the medication from the effects of the underlying disorder. This makes it difficult for researchers to determine whether the few associations observed between the groups that were exposed to medication use or if they were caused by the presence of comorbidities. The researchers did not look at the long-term effects for the offspring.

The study revealed that babies whose mothers took ADHD medication during pregnancy were at a slightly higher risk of admission to the neonatal care unit (NICU), compared to those whose mothers did not use any medication during pregnancy or had quit taking the medication prior to or during pregnancy. This was due to central nervous system disorders, and the increased risk for admission did not appear to be influenced by which stimulant medications were used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher chance of having a caesarean section or a baby that scored low on the Apgar scale (less than 7). These increases appear to be unrelated to the type of medication taken during pregnancy.

The researchers suggest that the risk of a small amount with the use of ADHD medications during early pregnancy could be offset by the greater benefits to both mother and child of continued treatment for the woman's condition. Doctors should discuss with their patients about this and, if possible, help them improve coping skills which could reduce the impact of her disorder in her daily functioning and her relationships.

Interactions with Medication

Doctors are increasingly faced with the decision of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are often made without clear and reliable evidence. Instead, physicians must consider their own expertise in conjunction with the experiences of other doctors and the research that has been conducted on the subject.

Particularly, the subject of potential risks to the baby can be a challenge. The research that has been conducted on this topic is based on observations instead of controlled studies and the results are contradictory. In addition, most studies limit their analysis to live births, which may underestimate severe teratogenic effects that cause abortion or termination of the pregnancy. The study presented in the journal club addresses these issues by analyzing both information on deceased and live births.

Conclusion Some studies have found an association between ADHD medications and certain birth defects, other studies have not found a correlation. Most studies show an unintended, or slight negative effect. As a result, a careful risk/benefit assessment must be conducted in every situation.

It isn't easy, but not impossible for women with ADHD to stop taking their medication. In a recent piece published in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of being isolated. Furthermore, a loss of medication may affect the ability to complete job-related tasks and drive safely that are crucial aspects of a normal life for a lot of people with ADHD.

She suggests that women who aren't sure whether to take the medication or stop it due to their pregnancy educate family members, coworkers and acquaintances about the condition, its impact on daily functioning and the benefits of continuing the current treatment regimen. It will also help a woman feel confident about her decision. It is important to note that some drugs can pass through the placenta, therefore, if a patient decides to stop taking her ADHD medication during pregnancy and breastfeeding, she should be aware that the effects of the drug can be transferred to the infant.

Birth Defects and Risk of

As the use and misuse of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD), increases, so does concern about the potential adverse effects of the drugs on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body knowledge on this topic. Using two massive data sets researchers were able to analyze more than 4.3 million pregnancies to determine whether stimulant medications increased the risk of birth defects. While the overall risk remains low, the researchers did find that first-trimester exposure to ADHD medications was linked to a slightly higher rate of certain heart defects such as ventriculo-septal defect (VSD).

The authors of the study did not discover any connection between early use of medication and congenital anomalies such as facial deformities or club feet. The results are in the same vein as previous studies which showed the existence of a slight, but significant increase in the number of cardiac malformations among women who began taking ADHD medication before pregnancy. The risk grew in the latter half of pregnancy, when a lot of women decide to stop taking their ADHD medications.

Women who took ADHD medications during the first trimester of their pregnancies were also more likely to undergo caesarean sections, a low Apgar score after delivery and a baby who needed breathing assistance at birth. However the researchers of the study were not able to eliminate selection bias by limiting the study to women who did not have other medical issues that could have contributed to these findings.

The researchers hope their study will serve to inform the clinical decisions of doctors who treat pregnant women. The researchers suggest that, while discussing benefits and risks are important, the decision on whether to continue or stop medication should be made in light of the severity of each woman's ADHD symptoms and her needs.

The authors also warn that, while stopping the medication is an alternative, it is not an option that is recommended due to the high prevalence of depression and other mental health problems in women who are pregnant or who are recently post-partum. Further, the research suggests that women who choose to stop taking their medication are more likely to experience a difficult time adjusting to life without them after the baby's arrival.

Nursing

It can be a challenge to become a mother. Women with ADHD who must work through their symptoms while attending doctor appointments and making preparations for the arrival of a child and adjusting to new household routines are often faced with a number of difficulties. This is why many women elect to continue taking their ADHD medication throughout the pregnancy.

The risk for nursing infant is low because the majority of stimulant medication passes through breast milk at a low level. The rate of medication exposure can vary depending upon the dosage, frequency of administration and the time of day. Additionally, different what medications are prescribed for adhd enter the baby’s system via the gastrointestinal tract, or through breast milk. The impact on a newborn's health is not fully understood.

Because of the lack of research, some physicians might be tempted to stop taking stimulant drugs during the pregnancy of a woman. This is a difficult choice for the patient, who must balance the benefit of continuing her medication against the potential dangers to the fetus. Until more information is available, doctors should inquire with all pregnant patients about their history of ADHD and whether they are planning or taking to take medication during the perinatal period.

Many studies have shown that women can continue taking their ADHD medication for adhd And bipolar safely while breastfeeding and during pregnancy. In response, a growing number of patients are opting to continue their medication. They have discovered after consulting with their doctors that the benefits of retaining their current medication far outweigh any potential risks.

Women with ADHD who plan to breastfeed should seek the advice of a specialist psychiatrist before becoming pregnant. They should discuss their medication with their physician and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation should also be offered to help pregnant people with ADHD recognize their symptoms and underlying disorder Learn about the available treatments and to reinforce existing strategies for coping. This should be a multidisciplinary effort with the GPs, obstetricians and psychiatrists. Pregnancy counselling should include the discussion of a treatment plan for both the mother and child, monitoring for signs of deterioration, and, if necessary, adjustments to the medication regimen.